Oncolytics Biotech - ADR Peer Comparison

$0.83

$-0.02 (-2.68%)

As on 28-Aug-2026 13:36EDT

Market cap

$108 Mln

Revenue (TTM)

$0 Mln

P/E Ratio

--

P/B Ratio

1055

Div. Yield

0 %

Edit

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
Market cap ($ Mln)	108	760
Revenue ($ Mln)	--	--
Net Profit ($ Mln)	-38.21	-24.75
Net Margin (%)	--	--
RoE (%)	--	-12.45
Price to Earnings	--	--
Price-To-Book	1,055.04	3.48

Cashflow
Ratios

Cashflow ($ Mln)

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
Cash From Operating Activities	-20.11	-8.69
Cash Flow from Investing Activities	-0.01	--
Cash from Financing Activities	14.12	85.57
Net Cash Inflow / Outflow	--	--

Ratios

Profitability Ratios

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
ROCE (%)	-2,206.47	-27.85
ROE (%)	-7,467.16	-12.45
ROA (%)	-185.16	-7.34
EBIT Margin (%)	--	--
Net Margin (%)	--	--
Cash Profit Margin (%)	--	--

Growth Ratios

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
Revenue Growth (%)	--	--
EBIT Growth (%)	-31.94	-264.98
Net Profit Growth (%)	-63.87	-177.52
EPS Growth (%)	-21.75	-89.76
Book Value Growth (%)	-176.97	328.64

Valuation Ratios

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
Price / Earnings	-3.28	-35.55
Price / Book Value	-18.11	5.30
Dividend Yield (%)	--	--
EV/EBITDA	-3.07	-28.96
Market Cap ($ Cr)	--	--

Solvency Ratios

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
Debt to Equity	0.00	0.00
Short term debt to equity ratio	-0.02	0.00
Current Ratio	1.35	121.97
Quick Ratio	1.35	121.97
Interest Coverage	--	-1,513.67

Operating Efficiency Ratios

	Oncolytics Biotech - ADR	Bright Minds Biosciences Inc (DRUG)
Debtors to sales (%)	--	--
Asset Turnover	0.00	0.00
Receivable days	--	--
Inventory Days	--	--
Payable days	15,379.49	7,007.85
Cash Conversion Cycle	--	--

*TTM (Trailing Twelve Months) data based on income statement of last 4 quarters and interim half yearly balance sheet.

Annual
Quarterly